Your session is about to expire
What is Cotempla Xr-Odt
MethylphenidateThe Generic name of this drug
Treatment SummaryMethylphenidate is a stimulant drug used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. It is commonly known as Ritalin, Concerta, or Biphentin. It's used in combination with other treatments such as psychological or cognitive behaviour therapy to reduce symptoms of ADHD like distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Methylphenidate is considered the most effective and widely used treatment for ADHD and is recommended by medical professionals as a first-line option for children, adolescents, and adults. The drug works by increasing levels
Methylphenidate Hydrochlorideis the brand name
Cotempla Xr-Odt Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Methylphenidate Hydrochloride
Methylphenidate
1955
490
Effectiveness
How Cotempla Xr-Odt Affects PatientsMethylphenidate is a combination of two forms of the same drug, one of which is more powerful than the other. It works by binding to the dopamine-rich areas of the prefrontal cortex, which is believed to be linked to Attention Deficit Hyperactivity Disorder (ADHD). Studies in animals have shown that methylphenidate increases movement and causes repetitive behaviors.
How Cotempla Xr-Odt works in the bodyMethylphenidate helps to treat Attention Deficit Hyperactivity Disorder (ADHD) by increasing the amount of neurotransmitters norepinephrine and dopamine in the brain. When taken in lower doses, this increases activity in the prefrontal cortex, which can reduce impulsivity and improve cognitive functions like attention and memory. The more you take, the more it activates other parts of the brain, which can lead to impaired cognition and other side effects. Clinical findings suggest that methylphenidate helps correct an imbalance of dopamine-related genes, which may be the cause of ADHD.
When to interrupt dosage
The advised dosage of Cotempla Xr-Odt is contingent upon the identified condition. The quantity of dosage fluctuates, in light of the administration technique provided in the table below.Condition
Dosage
Administration
Attention Deficit Hyperactivity Disorder
20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg
, Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Transdermal, Patch, Patch - Transdermal, Suspension, extended release, Suspension, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Narcolepsy
20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg
, Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Transdermal, Patch, Patch - Transdermal, Suspension, extended release, Suspension, extended release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral
Warnings
Cotempla Xr-Odt ContraindicationsCondition
Risk Level
Notes
advanced arteriosclerosis
Do Not Combine
Gilles de la Tourette syndrome
Do Not Combine
Thyrotoxicosis
Do Not Combine
Pulse Frequency
Do Not Combine
Open-angle glaucoma
Do Not Combine
Hypertensive disease
Do Not Combine
Pulse Frequency
Do Not Combine
Tension
Do Not Combine
Generalized Anxiety Disorder
Do Not Combine
symptomatic cardiovascular disease
Do Not Combine
Gilles de la Tourette's Syndrome
Do Not Combine
Pheochromocytomas
Do Not Combine
Tic, Motor
Do Not Combine
Agitation
Do Not Combine
Common Cotempla Xr-Odt Drug Interactions
Drug Name
Risk Level
Description
Desflurane
Major
Methylphenidate may increase the hypertensive activities of Desflurane.
Diethyl ether
Major
Methylphenidate may increase the hypertensive activities of Diethyl ether.
Enflurane
Major
Methylphenidate may increase the hypertensive activities of Enflurane.
Halothane
Major
Methylphenidate may increase the hypertensive activities of Halothane.
Isoflurane
Major
Methylphenidate may increase the hypertensive activities of Isoflurane.
Cotempla Xr-Odt Toxicity & Overdose RiskOverdosing on phenobarbital can lead to vomiting, restlessness, trembling, increased reflexes, muscle twitching, seizures (possibly followed by unconsciousness), feeling of happiness, confusion, hallucinations, delirium, sweating, flushing, headache, high fever, rapid heart rate, irregular heartbeats, high blood pressure, enlarged pupils, and dry mouth. The toxic dose in mice is 190mg/kg when taken orally.
Cotempla Xr-Odt Novel Uses: Which Conditions Have a Clinical Trial Featuring Cotempla Xr-Odt?
84 active clinical trials are presently exploring the possibility of using Cotempla Xr-Odt to manage Attention Deficit Hyperactivity Disorder.Condition
Clinical Trials
Trial Phases
Attention Deficit Hyperactivity Disorder
71 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1
Narcolepsy
10 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4, Phase 1
Patient Q&A Section about cotempla xr-odt
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Can you swallow Cotempla XR-ODT?
"The tablet needs to be in contact with your child's saliva in order to dissolve and be swallowed. There is no need for any liquid. Your child should not chew or crush the tablet, and it should be taken at the same time each day with or without food."
Answered by AI
Is Cotempla the same as Adderall?
"These new amphetamine-based drugs are similar to Adderall, a medication that has been available for years. The main difference between these new drugs and Adderall is that the former contains amphetamine instead of methylphenidate."
Answered by AI
Is Cotempla the same as Ritalin?
"The drug Cotempla XR-ODT contains the same active ingredient as other drugs like Ritalin and Daytrana, but instead of having to chew or drink water with it, the patient can let it dissolve in their mouth. The FDA has labeled it as a federally controlled substance (CII) because it has the potential to be abused or lead to dependence."
Answered by AI
What is Cotempla XR-ODT used for?
"This medication is used to treat attention deficit hyperactivity disorder - ADHD. It inhibiting the reuptake of dopamine and norepinephrine into the pre-synaptic neuron, which leads to increased concentrations of dopamine and norepinephrine in the synaptic cleft. Methylphenidate belongs to a class of drugs known as Stimulant."
Answered by AI